Each week we highlight five things affecting the life sciences industry. Here’s the latest.
Extreme heat and its impact on medicines
- Extreme heat can affect the efficacy and safety of medicines, potentially causing them to degrade or lose potency if not stored properly, according to experts.
- According to Reuters, individuals taking medications, especially those with conditions like diabetes or heart disease, need to be vigilant about storage recommendations and watch for signs of altered drug effectiveness during heatwaves.
FDA’s device center director to retire
- Jeff Shuren, director of the U.S. Food and Drug Administration’s Center for Devices and Radiological Health, announced his retirement after 15 years of service.
- According to Fierce Biotech, Dr. Michelle Tarver will serve as the acting director, bringing her extensive experience in patient science and engagement to the role.
FTC’s battle with pharmacy benefit managers could reshape pharmaceutical industry
- The Federal Trade Commission’s scrutiny of pharmacy benefit managers aims to address anti-competitive practices that affect drug prices and market accessibility.
- Forbes reports that the outcome of this battle could lead to significant regulatory changes, promoting transparency and potentially lowering medication costs for consumers.
EU regulator backs Wegovy to lower heart risks
- The European Medicines Agency has endorsed the use of Novo Nordisk’s weight-loss drug Wegovy to reduce the risk of heart disease in overweight and obese individuals, reports Reuters.
- This recommendation follows a significant trial showing that Wegovy lowered the risk of major cardiovascular events by 20%, marking a potential expansion of its use beyond weight management.
AI-powered clinical trial funding program launched
- A new artificial intelligence-powered program has been introduced to streamline funding for clinical trials, enhancing efficiency and reducing costs.
- According to Fierce Biotech, the initiative uses machine learning to identify promising trials and optimize investment strategies, potentially accelerating the development of new treatment.
For more insights in life sciences, check out RSM’s industry outlook.
